Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Investor Presentation (December 2023)
9 slides from Bioporto A/s's investor presentation, Dec 11, 2023
Slide 1: Empowering Early Detection of Kidney Injury
Empowering Early Detection of Kidney Injury December 11, 2023 © Copyright BioPorto | 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: FDA Grants 510(k) Marketing Clearance for ProNephro AKI (NGAL) for Pediatric AKI Risk Assessment
FDA Grants 510(k) Marketing Clearance for ProNephro AKITM (NGAL) for Pediatric AKI Risk Assessment © Copyright BioPorto | 3
Slide 4: ProNephro AKI (NGAL): Indications for Use
Indications for Use ProNephro AKI (NGAL): Indications for Use Indications for Use: Immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine. Determination of NGAL is intended to be used in conjunction with clinical evaluation in pedi
Slide 5: Acute Kidney Injury (AKI) — An Unmet Clinical Need
Acute Kidney Injury (AKI) — An Unmet Clinical Need • AKI, is an abrupt loss of kidney function that develops rapidly over a few hours or days. • Symptoms may include decreased urinary output, swelling due to fluid retention, nausea, fatigue, and shortness of breath. Often painless without symptoms.
Slide 6: NGAL Values Actively Direct Interventions in Critical Care
NGAL Values Actively Direct Interventions in Critical Care • Administer fluids “I love NGAL because when it’s LOW, I know • Diuretics and imaging I can be aggressive with diuretics.” Monitor Stable – Pediatric Critical Care Physician Low Values kidney NGAL “I have changed my management decisions on
Slide 7: Track Record of Execution and Clear Commercial Roadmap
Track Record of Execution and Clear Commercial Roadmap Reimbursement/Health New Management Team, focused on Economics and Start clinical data studies • Completing clinical study, Outcomes Research to support prioritized adult • Navigate FDA indication “HEOR” study • Drive commercialization to Roche
Slide 8: US TAM Growth: Broadening Compatibility & Adult Label Expansion
US TAM Growth: Broadening Compatibility & Adult Label Expansion TAM $1.2B3 Addition of 3rd Adult Label PEDIATRIC ADULT Indication United States: $1.2B FDA Label Expansion with 1st Global: $3B Adult Indication Addition of 2nd Adult Label Indication Indication Expansion Beyond ICU Expansion of Instrum
Slide 9: Contacts
Contacts: Denmark: HC Andersen Capital P: +45 4529 0000 E: investor@bioporto.com US: Ashley R. Robinson, LifeSci Advisors P: +1 617 430 7577 E: arr@lifesciadvisors.com CPH: BIOPOR © Copyright BioPorto | 9